High Non-HDL-C Levels in Adolescents tied to CAC in Mid-adulthood

Written By :  MD Bureau
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-02-17 01:15 GMT   |   Update On 2021-02-17 06:55 GMT
Advertisement

Biological processes underlying the causes of heart disease begin years before the emergence of clinical symptoms. In a recent study published in the JAMA Cardiology on January 27, 2021, researchers have reported that the elevated Non–high-density lipoprotein cholesterol (non-HDL-C) levels at all stages of life are associated with Coronary Atherosclerosis in mid-adulthood. They further reported that the elevated non-HDL-C levels in adolescents may indicate the presence of Coronary Artery Calcification (CAC) in mid-adulthood. They recommend greater awareness of the importance of elevated non–HDL-C among adolescence.

Advertisement

Low-density lipoprotein cholesterol (LDL-C) is an important risk factor for heart disease and is the primary target in the management of adult dyslipidemia. The non–HDL-C encompasses a greater number of atherogenic lipids and lipoproteins. It might provide a better marker of heart disease risk attributable to dyslipidemia. Elevated non–HDL-C is associated with the presence of coronary artery calcification (CAC), a marker of heart disease in adulthood. Yet, the relative importance of non–HDL-C levels at different life stages for predicting atherosclerotic disease in later life remains unclear. Therefore, Dr Matthew K. Armstrong and colleagues conducted a study, to identify the relative association of non-HDL-C measured at distinct life stages (adolescence, young adulthood, mid-adulthood) with the presence of CAC measured in mid-adulthood.

The Cardiovascular Risk in Young Finns Study was a multicenter, population-based cohort study that began in 1980 with subsequent follow-up in 1983, 1986, 1989, 1992, 2001, and 2007. Researchers analyzed the data of 589 participants from this 28 years study by February 2020. They noted the non-HDL-C levels at 3 life stages including adolescence (aged 12-18 years), young adulthood (aged 21-30 years), and mid-adulthood (aged 33-45 years). In 2008, CAC was determined using computed tomography. Researchers categorized the CAC as 0 (no CAC, Agatston score = 0) or 1 (presence of CAC, Agatston score ≥1) for the purpose of analysis. They used Bayesian relevant life course exposure model to determine the relative association between non–HDL-C at each life stage and the presence of CAC in mid-adulthood.

Key findings of the study were:

• Researchers adjusted the model for year of birth, sex, body mass index, systolic blood pressure, blood glucose level, smoking status, lipid-lowering and antihypertensive medication use, and family history of heart disease.

• They noted that the cumulative exposure to non–HDL-C across all life stages was associated with CAC (odds ratio [OR], 1.50).

• They found that the ORs of CAC presence due to elevated non–HDL-C exposure during young adulthood and mid-adulthood were 1.14 and 1.12, respectively.

• However, they noted that exposure to non–HDL-C during adolescence had the strongest association—with an OR of 1.16 (95%, 1.01-1.46).

The authors concluded, "These data suggest that elevated non–HDL-C levels at all life stages are associated with coronary atherosclerosis in mid-adulthood. However, adolescent non–HDL-C levels showed the strongest association with the presence of CAC in mid-adulthood".

They further added, "Altogether, early screening, identification, and management of elevated non–HDL-C levels may represent an important goal toward reducing the burden of heart disease in adulthood".

For further information:

https://jamanetwork.com/journals/jamacardiology/fullarticle/2775672


Tags:    
Article Source :  JAMA Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News